215 related articles for article (PubMed ID: 9215839)
1. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
2. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
3. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
[TBL] [Abstract][Full Text] [Related]
4. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in peripheral T-cell malignancies.
Dearden C
Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
[TBL] [Abstract][Full Text] [Related]
7. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE
Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283
[TBL] [Abstract][Full Text] [Related]
9. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
[TBL] [Abstract][Full Text] [Related]
14. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
Walsh M; Chaudhry A; Jayne D
Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
[TBL] [Abstract][Full Text] [Related]
16. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
Dumont FJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia.
Tuset E; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Leuk Lymphoma; 2001; 42(6):1379-83. PubMed ID: 11911422
[TBL] [Abstract][Full Text] [Related]
18. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
[TBL] [Abstract][Full Text] [Related]
20. Campath-1H monoclonal antibody therapy.
Flynn JM; Byrd JC
Curr Opin Oncol; 2000 Nov; 12(6):574-81. PubMed ID: 11085457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
